Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cynata Therapeutics Ord Shs V.CYP


Primary Symbol: CYYNF

Healthcare Biotechnology
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.


OTCPK:CYYNF - Post by User

Cynata Therapeutics Ord Shs > OEM's are desperate for supply
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(283)
•••
Comment by metalhead666on Aug 16, 2022 7:06pm
261 Views
Post# 34900803

RE:RE:RE:RE:RE:RE:RE:RE:RE:OEM's are desperate for supply

RE:RE:RE:RE:RE:RE:RE:RE:RE:OEM's are desperate for supplyWelcome to mining!  It always takes longer than you want. Always.  The feasibility study will be a big deal. From there they can move towards a construction decision, financing and eventual production. With a feasibility study in hand they can start cutting deals too. These things take forever and do try your patience but....we can rip to NPV value of considerably more than a Billion$  With lithium prices where they are we can quickly rise to a share price of $5 $6 $7 $8 or more.  The prefeasibility had an NPV of 1 billion...the feasibility should be considerably greater.  1x that is a $5 stock.  Ioner trades at 1x NPV with their feasibility study complete. We should follow suit.  Besides Albermarle no one else is going to own the Clayton Valley. We have the water. That took some slick dealing, a court case, time, money but we have it now.  The test plant is performing. We have a large land package with good material. I see no reason we don't trade north of $5 by this time next year or sooner
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities